肝细胞癌根治性切除术后辅助经动脉化疗栓塞:一项随机、开放标签、3期试验
这项随机3期试验将332例AJCC TNM I–II期肝细胞癌根治性切除术后患者按1:1分为辅助TACE组(n=166)与观察组(n=166),主要终点无复发生存(RFS)在两组间无显著差异(HR 0.88,95%CI 0.62–1.24,p=0.468),总生存亦无显著差异(HR 1.06,95%CI 0.63–1.76,p=0.838),两组均无≥3级不良事件或治疗相关死亡。
要点
- 根治性切除术后辅助TACE未延长I–II期肝细胞癌患者的RFS(HR 0.88,p=0.468)。
- 总生存两组无显著差异(HR 1.06,95%CI 0.63–1.76,p=0.838)。
- 两组均未发生≥3级不良事件或治疗相关死亡。
核心结论
- 在AJCC TNM I或II期肝细胞癌患者中,根治性切除术后辅助TACE与RFS或总生存延长无关。
研究设计与样本
- 随机、开放标签、3期试验,组织学确诊的AJCC TNM I和II期肝细胞癌患者按1:1随机分配至辅助TACE组或观察组。
- 2014年3月至2021年6月共332例患者纳入意向治疗(ITT)人群,TACE组n=166,观察组n=166。
- 主要终点为ITT人群的无复发生存(RFS),次要终点包括总生存和安全性。
主要发现
- ITT人群RFS两组相当:中位均未达到,HR 0.88(95%CI 0.62–1.24,p=0.468)。
- 1、3、5年RFS率:辅助TACE组分别为87.3%(95%CI 81.2–91.5)、70.7%(95%CI 63.0–77.0)、60.6%(95%CI 51.9–68.3);观察组分别为84.8%(95%CI 78.3–89.5)、69.3%(95%CI 61.6–75.8)、58.1%(95%CI 49.5–65.8)。
- ITT人群总生存两组相当:中位均未达到,HR 1.06(95%CI 0.63–1.76,p=0.838)。
- 两组均无≥3级不良事件或治疗相关死亡。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The role of adjuvant transarterial chemoembolization (TACE) for HCC following curative resection remains controversial. We aimed to determine the effectiveness of postoperative adjuvant TACE in patients with HCC. APPROACH AND RESULTS: In this randomized phase 3 trial, histologically confirmed patients with HCC (American Joint Committee on Cancer TNM stage I and II) were randomly assigned (1:1) to adjuvant TACE or observation groups. The primary endpoint was recurrence-free survival (RFS) in the intention-to-treat (ITT) population. The secondary endpoints included overall survival and safety. A total of 332 patients (ITT population) were randomly assigned to the TACE group (n=166) or the observation group (n=166) between March 2014 and June 2021. The RFS was comparable between the 2 groups from the ITT population (median, both unreached; HR, 0.88; 95% CI: 0.62-1.24; p =0.468). The RFS rates at 1, 3, and 5 years were 87.3% (95% CI: 81.2-91.5), 70.7% (95% CI: 63.0-77.0), and 60.6% (95% CI: 51.9-68.3) in the adjuvant TACE group and 84.8% (95% CI: 78.3-89.5), 69.3% (95% CI: 61.6-75.8), and 58.1% (95% CI: 49.5-65.8) in the observation group, respectively. The overall survival was comparable between the TACE group and the observation group in the ITT population (median, both unreached, HR, 1.06; 95% CI: 0.63-1.76; p =0.838). There was no grade ≥ 3 adverse event or treatment-related death in either group. CONCLUSIONS: Postoperative adjuvant TACE was not associated with prolonged RFS or overall survival in patients with American Joint Committee on Cancer TNM stage I or II HCC.
引用
- Ma T, Bai X, Zhang Q, et al. Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection: A randomized, open-label, phase 3 trial. Hepatology. 2025. PMID: 39808820. doi:10.1097/HEP.0000000000001233
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。